Abstract
Since the implementation of the tilt table test in 1986 for diagnosis of patients with recurrent syncope of unknown cause, neurocardiogenic syncope became the most common cause of syncope. Regarding its importance in public health, its pathophysiologic mechanisms are not yet clear, making difficult a therapeutic approach.
The initial treatment for neurocardiogenic syncope comprises education, volume expansion strategies and orthostatism tolerance maintenance. On the other hand, multiple alternatives have emerged for a pharmacological treatment based on the different physiopatologic theories.
This article shows the existing evidence on neurocardiogenic syncope treatment and serves as a guide about the different therapeutic options for these patients (Acta Neurol Colomb 2005;21:126-133).
References
Kapoor WN. Syncope. N Eng J Med 2000; 343: 1856-1862.
Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Eng J Med 2002; 347: 878-885.
Brignole M, Alboni P, Benditt D, et al. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001; 22: 1256-1306.
Scarabelli CC, Scarabelli TM. Neurocardiogenic Syncope. BMJ 2004; 329: 336-341.
Mosqueda-García R, Furlan R, Tank J, Fernandez- Violante R. The elusive pathophysiology of neurally mediated syncope. Circulation 2000; 102:2898-2906.
Morillo CA, Villar JC. Neurocardiology. Neurogenic syncope. Baillieres Clin Neurol 1997; 6: 357-380.
Morillo CA, Ellenbogen KA, Klein GJ. Head-up tilt testing: the balance of evidence. Br Heart J 1995; 73: 583.
Kapoor WK. Is there an effective treatment for neurally mediated syncope? JAMA 2003; 289:2272-2275.
Morillo CA, Klein GJ, Zandri S, Yee R. Diagnostic accuracy of a low-dose isoproterenol head-up tilt protocol. Am Heart J 1995; 129: 901-906.
Raviele A, Giada F, Brignole M, et al. Comparison of diagnostic accuracy of sublingual nitroglycerin test and low-dose isoproterenol test in patients with unexplained syncope. Am J Cardiol 2000; 85:1194-1198.
Natale A, Akhtar M, Jazayeri M, et al. Provocation of hypotension during head-up tilt testing in subjects with no history of syncope or presyncope. Circulation 1995; 92: 54-58.
Foglia-Manzillo G, Giada F, Beretta S, Corrado G, Santarone M, Raviele A. Reproducibility of head-up tilt testing potentiated with sublingual nitroglycerin in patients with unexplained syncope. Am J Cardiol 1999; 84:284-288.
Del Rosso A, Bartoletti A, Bartoli P, et al. Methodology of head-up tilt testing potentiated with sublingual nitroglycerin in unexplained syncope. Am J Cardiol 2000; 85:1007-1011.
Natale A, Sra J, Akhtar M, et al. Use of sublingual nitroglycerin during head-up tilt-table testing in patients >60 years of age. Am J Cardiol 1998; 82:1210-1213.
Grubb BP, Jorge Sdo C. A review of the classification, diagnosis, and management of autonomic dysfunction syndromes associated with orthostatic intolerance. Arq Bras Cardiol 2000; 74:545-552.
Silvani S, Padoan G, Guidi AR, Bianchedi G, Maresta A. Cerebral vasoconstriction in neurally mediated syncope: relationship with type of head up tilt test response. Ital Heart J 2003; 4:768-775.
Lurie KG, Benditt D. Syncope and the autonomic nervous system. J Cardiovasc Electrophysiol 1996; 7:760-776.
Hainsworth R. Pathophysiology of syncope. Clin Auton Res 2004; 14:I/18-I/24.
Thompson HL, Wright K, Frenneaux M. Baroreflex sensitivity in patients with vasovagal syncope. Circulation 1997; 95:395-400.
Morillo CA, Eckberg DL, Ellenbogen KA et al. Vagal and sympathetic mechanisms in patients with orthostatic vasovagal syncope. Circulation 1997; 96:2509-2513.
Kaufmann H. Neurally mediated syncope: pathogenesis, diagnosis, and treatment. Neurology 1995; 45:S12-S18.
Morillo CA, Ellenbogen KA, Fernando Pava L. Pathophysiologic basis for vasodepressor syncope. Cardiol Clin 1997; 15:233-249.
Morillo CA, Baranchuk A. Current Management of Syncope: Treatment Alternatives. Curr Treat Options Cardiovasc Med 2004; 6:371-383.
Sheldon R, Morillo C, Krahn A. Management of vasovagal syncope: 2004. Expert Rev Cardiovasc Ther 2004; 2: 915-923.
Wieling W, Colman N, Paul Krediet CT, Freeman R. Nonpharmacological treatment of reflex syncope. Clin Auton Res 2004; 14:I/62-I/70.
Krediet CT, van Dijk N, Linzer M, van Lieshout JJ, Wieling W. Management of vasovagal syncope: controlling or aborting faints by leg crossing and muscle tensing. Circulation 2002; 106:1684-1689.
Lieshout JJv, Pott F, Madsen PL, Goudoever JV, Secher NH. Muscle tensing during standing: Effects on cerebral tissue oxigenation and cerebral artery blood velocity. Stroke 2001; 32:1546-1551.
Morillo CA, Baranchuk A. Current Management of Syncope: Treatment Alternatives. Curr Treat Options Cardiovasc Med 2004; 6:371-383.
Brignole M, Croci F, Menozzi C, et al. Isometric arm counterpressure maneuvers to abort impending vasovagal syncope. J Am Coll Cardiol 2002; 40:2054-2060.
Mtinangi BL, Hainsworth R. Increased orthostatic tolerance following moderate excercise training in patients with unexplained syncope. Heart 1998; 80:596-600.
Mtinangi BL, Hainsworth R. Effect of moderate excercise training on plasma volume, baroreceptor sensitivity and orthostatic tolerance in healthy subjects. Exp Physiol 1999; 84:121-130.
Ector H, Reydrouck T, Heidbuchel H, Gewillig M, Van de Werf F. Tilt training: a new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance. Pacing Clin Electrophysiol 1998; 21:193-196.
Di Girolamo E, Di Iorio C, Leonzio L, Sabatini P, Barsotti A. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study. Circulation 1999; 100:1798-1801.
Reydrouck T, Heidbuchel H, Van de Werf F. Long-term follow-up results of tilt training therapy in patients with recurrent neurocardiogenic syncope. Pacing Clin Electrophysiol 2002; 25:1441-1446.
El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart 1996; 75:134-140.
Cooper VL, Hainsworth R. Effects of dietary salt on orthostatic tolerance, blood pressure and baroreceptor sensitivity in patients with syncope. Clin Auton Res 2002; 12:236-241.
Muller G, Deal B, Strasburger JF, Benson DW Jr. Usefulness of metoprolol for unexplained syncope and positive response to tilt testing in young persons. Am J Cardiol 1993; 71:592-595.
Sra JS, Murthy VS, Jazayeri MR, et al. Use of intravenous esmolol to predict efficacy of oral adrenergic blocker therapy in patients with neurocardiogenic syncope. J Am Coll Cardiol 1993; 19:402-408.
Flevari P, Livanis EG, Theodorakis GN, Zarvalis E, Mesiski T, Kremastinos DT. Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propanolol, nadolol and placebo on syncope recurrence and patients well-being. J Am Coll Cardiol 2002; 40:499-504.
Madrid AH, Ortega J, Rebollo JG, et al. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo controlled study. J Am Coll Cardiol 2001; 37:554-559.
Alegria JR, Gersh BJ, Scott CG, Hodge DO, Hammill SC, Shen WK. Comparison of frecuency of recurrent syncope after beta-blocker therapy versus conservative management for patients with vasovagal syncope. Am J Cardiol 2003; 92:82-84.
Kaufmann H, Freeman R. Pharmacological treatment of reflex syncope. Clin Auton Res 2004; 14:I/71-I/75.
Scott WA, Pongiglione G, Bromberg BI, et al. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995; 76:400-402.
Rowe PC, Calkins H, DeBusk K, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA 2001; 285:52-59.
Salim MA, Di Sessa TG. Effectiveness of fludrocortisone and salt in preventing syncope recurrence in children: a double-blind, placebo-controlled, randomized trial. J Am Coll Cardiol 2005; 45:484-488.
Fuller RW. Neural functions of serotonin. Scientific Amercian Sci Med 1995; 4: 48-57.
Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, A selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo- controlled study. J Am Coll Cardiol 1999; 33:1227-1230.
Grubb BP, Samoil D, Kosinski D, Wolfe D, Lorton M, Madu E. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension. Am J Med 1994; 97:366-368.
Takata TS, Wasmund SL, Smith ML, et al. Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers. Circulation 2002; 106:1500-1504.
Mitro P, Trejbal D, Raybár R. Midodrine hydrochloride in the treatment of vasovagal syncope. PACE 1999; 22:1620-1624.
Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study. Ann Neurol 2002; 52:342-345.
Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine for neurogenic orthostatic hypotension Reply. JAMA 1997; 278:388.
Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart.1998; 79:45-49.
Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998; 51:120-124.
Raviele A, Brignole M, Sutton R, et al. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: a double-blind, randomized, placebo- controlled trial. The Vasovagal Syncope International Study. Circulation. 1999; 99:1452-1457.
Morillo CA, Leitch JW, Yee R, Klein GJ. A placebo- controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol. 1993; 22:1843-1848.
Sutton R, Brignole M, Menozzi C, et al. Dual- chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators. Circulation. 2000; 102:294-299.
Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American Vasovagal Pacemaker Study (VPS) A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 1999; 33:16-20.
Connolly SJ, Sheldon R, Thorpe KE, et al. VPS II Investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA 2003; 289:2224-2249.
Raviele A, Giada F, Menozzi C, et al. Vasovagal Syncope and Pacing Trial Investigators. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE). Eur Heart J 2004; 25:1741-1748.
Grubb BP. Neurocardiogenic Syncope. N Eng J Med
; 352:1004-1010.
Sutton R, Petersen M, Brignole M, Raviele A, Menozzi C, Giani P. Proposed classification for tilt induced vasovagal syncope. Eur J Cardiac Pacing Electrophysiol 1992; 3:180-183.
Brignole M, Menozzi C, Del Rosso A, et al. New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification. Analysis of the pre- syncopal phase of the tilt test without and with nitroglycerin challenge. Vasovagal Syncope International Study. Europace 2000; 2:66-76.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.